CVB - CurveBeam AI | Aussie Stock Forums

[ad_1]

Half Year Financial Statements Released Period Ended 31 Dec 2023

Executive Summary
o Revenue
o H1 FY2024 revenue was $3.53m, versus $2.18m for the comparative period H1 FY2023, and $5.57m for the pro-forma revenue for H1 FY2023.
o Pro-Forma comparative period included:
§ Deliveries of back orders following the COVID related chip shortage in FY22, clearing in early FY23.
§ Clearance of first and second generation discontinued products.
o HiRise™ orders
o 7 Purchase Orders versus 4 in H1 FY2023.
o Enhanced HiRise™
o The company continues development of an enhanced HiRise™, a higher X-ray energy CT with clearer images for a broader range of patient body types, required for custom protocols for hip and knee robotic surgical systems.
o The enhanced HiRise™ has been targeted to address feedback from group orthopaedic practices in the Company’s US prospect pipeline, who have not been
willing to commit until CurveBeam’s device can deliver the required datasets for keyrobotic surgical systems for knee and hip surgery. Once in place, the enhanced HiRise is expected to bring a step change in orders and adoption.

CurveBeam AI CEO Greg Brown said: “During our first half year as a listed company we have endeavored to respond to our circumstances and preserve cash as much as we can, while expeditiously developing an enhanced HiRise™ to meet market requirements. We continue to get consistent market feedback from orthopaedic surgeons that the HiRise™ offers an appealing solution, for group practice settings, to deliver in one visit a diagnosis and surgical plan. The company expects the enhanced HiRise™ to meet the specifications needed for fabricating custom cut guides for the various body types needed by Patient Specific Instrumentation and robotic surgical systems. The Company continues to target the use of the enhanced HiRise™ datasets in routine Total Knee Replacement planning, including robot assisted procedures by Q4 FY24. With this milestone we are targeting a step change in demand for the HiRise™.”

…. lots of proforma accounts ..
… and issues to “meet the market”. It’s not IBM

[ad_2]